Company intelligence / Profile preview

HealthTell

San Ramon, California, US

Ownership: Private
Employees: ~35
Development stage: Other

Overview

HealthTell has developed a platform for early disease detection using a drop of blood, with >95% accuracy in distinguishing >15 diseases, including cancer, autoimmune, infectious, and neurological disorders, using proprietary high-density peptide arrays to analyze immune system responses[3]. The technology is intended for both commercial diagnostic testing with physicians and pharmaceutical services for patient stratification and drug development[3][4].

Therapeutic areas: OncologyInfectious DiseasesImmunologyNeurology
Modalities: Diagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

Arizona State University (ASU) Biodesign Institute (spinout, academic collaboration)

Beyond the preview

Go deeper on HealthTell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealthTell.

Explore the full profile